Article
Crystal Growth & Design, Vol. 10, No. 5, 2010 2167
terms of supramolecular synthons mean that their composi-
tion, structure, and thermal stability remain largely unpre-
dictable with the exception that channel hydrates tend to
exhibit low thermal stability. It would therefore be appro-
priate to assert that water is indeed in many ways the nemesis
of crystal engineering.
(20) Henck, J. O.; Griesser, U. J.; Burger, A. Pharm. Ind. 1997, 59, 165–
169.
(21) (a) Allen, F. H.; Kennard, O. Chem. Des. Automat. News 1993, 8,
31–37. (b) Allen, F. H. Acta Crystallogr. 2002, B58, 380–388.
ꢀ
(22) Infantes, L.; Fabian, L; Motherwell, W. D. S. CrystEngComm
ꢀ
2007, 9, 65–71.
(23) (a) Khankari, R. K.; Grant, D. J. Thermochim. Acta 1995, 248
61–79. (b) Morris, K. R. Polymorphism in Pharmaceutical Solids;
Brittain, H. G., Ed.; Marcel Dekker, Inc.: New York, 1999; Vol. 95,
pp 125-181.
Supporting Information Available: X-ray crystallographic infor-
mation in CIF format, IR, DSC, TGA, PXRD are available free of
(24) (a) Infantes, L.; Chisholm, J.; Motherwell, S. CrystEngComm 2003,
5, 480–486. (b) Hickey, M. B.; Peterson, M. L.; Manas, E. S.; Alvarez,
€
J.; Haeffner, F.; Almarsson, O. J. Pharm. Sci. 2007, 96, 1090–1099.
References
(c) Kiang, Y.-H.; Xu, W.; Stephens, P. W.; Ball, R. G.; Yasuda, N. Cryst.
Growth Des. 2009, 9, 1833–1843. (d) Bak, A.; Cooke, M.; Kleppe, M.
Am. Pharm Rev. Sep/Oct 2008.
(1) (a) Pepinsky, R. Phys. Rev. 1955, 100, 971. (b) Schmidt, G. M. J. Pure
Appl. Chem. 1971, 27, 647–678. (c) Desiraju, G. R. Crystal Engineer-
ing: The Design of Organic Solids; Elsevier: Amsterdam, 1989. (d)
Etter, M. C. J. Am. Chem. Soc. 1982, 104, 1095–1096.
(2) (a) Moulton, B.; Zaworotko, M. J. Chem. Rev. 2001, 101, 1629–
1658. (b) Zaworotko, M. J. Cryst. Growth Des. 2007, 7, 4–9.
(3) Vippagunta, S. R.; Brittain, H. G.; Grant, D. J. W. Adv. Drug
Delivery Rev. 2001, 48, 3–26.
(25) (a) Falk, M.; Knop, O. Water: A Comprehensive Treatise; Franks,
F., Ed.; Plenum Press: New York, 1973; Vol. 2, pp 55-113. (b)
Authelin, J. R. Int. J. Pharm. 2005, 303, 37–53.
(26) Morris K. R.; Rodriguez-Hornedo, N. Encyclopedia of Pharma-
ceutical Technology; Swarbrick, J., Boylan, J., Eds; Marcel Dekker,
Inc: New York, 1993; Vol. 7, pp 393-440.
(4) Noyes, A. A.; Whitney, R. R. J. Am. Chem. Soc. 1897, 19, 930–934.
(5) Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. Pharm.
Res. 1995, 12, 413–420.
(6) (a) Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J.
J. Pharm. Sci. 2006, 95, 499–516. (b) Special issue on Pharmaceutical
Cocrystals Mol. Pharmaceutics 2007, 4, 299-486. (c) Shan, N.;
Zaworotko, M. J. Drug. Discov. Today 2008, 13, 440–446. (d)
Meanwell, N. A. Annu. Rep. Med. Chem. 2008, 43, 373–404. (e)
Schultheiss, N; Newman, A. Cryst. Growth Des. 2009, 9, 2950–2967.
(f) Stanton, M. K.; Bak, A. Cryst. Growth Des. 2008, 8, 3856–3862. (g)
(27) Byrn, S. R.; Lin, C. T. J. Am. Chem. Soc. 1976, 98, 4004.
(28) (a) Reutzel-Edens, S. M.; Bush, J. K.; Magee, P. A.; Stephenson,
G. A.; Byrn, S. R. Cryst. Growth Des. 2003, 3, 897–907. (b) Britain,
H. G.; Morris, K. G.; Boerrigter, S. X. M. Polymorphism in Pharma-
ceutical Solids; Brittain, H. G., Ed.; Informa Healthcare, Inc.:
New York, 2009; Vol. 192, pp 233-279.
(29) SMART-V5.625. Data Collection Software; Bruker-AXS: Madison,
Wisconsin, USA, 2001.
(30) APEX2 (Version 2008.1-0); Bruker: Madison, Wisconsin, USA,
2008.
€
Stahly, G. P. Cryst. Growth Des. 2009, 9, 4212–4229. (h) Aakeroy,
C. B.; Desper, J.; Fasulo, M.; Hussain, I.; Levin, B.; Schultheiss, N.
CrystEngComm 2008, 10, 1816–182.
(31) SAINT-V7.51A, Data Reduction Software, Bruker-AXS: Madison,
Wisconsin, USA, 2008.
(32) Sheldrick, G. M. SADABS. Program for Empirical Absorption
(7) Childs, S. L.; Chyall, L. J.; Dunlap, J. T.; Smolenskaya, V. N.; Stahly,
B. C.; Stahly, G. P. J. Am. Chem. Soc. 2004, 126, 13335–13342.
(8) McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.;
Cassidy, J.; Shet, M. S.; Mannion, R.; O’Donnell, E.; Park, A.
Pharm. Res. 2006, 23, 1888–1897.
(9) Hickey, M. B.; Peterson, M. L.; Scoppettuolo, L. A.; Morrisette,
S. L.; Vetter, A.; Guzman, H.; Remenar, J. F.; Zhang, Z.; Tawa,
M. D.; Haley, S.; Zaworotko, M. J.; Almarsson, O. Eur. J. Pharm.
Biopharm. 2007, 67, 112.
Correction; University of Gottingen: Germany, 1996.
(33) Sheldrick, G. M. SHELXTL, v. 6.10; Bruker-AXS Madison:
Wisconsin, USA, 2000.
(34) (a) Farrugia, L. J. Appl. Crystallogr. 1999, 32, 837–838. (b)
Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112–122. (c) Sheldrick,
G. M. Acta Crystallogr. 1990, A46, 467–473.
(35) (a) Fleischman, S. G.; Kuduva, S. S.; McMahon, J. A.; Moulton,
B.; Walsh, R. B.; Rodriguez-Hornedo, N.; Zaworotko, M. J. Cryst.
€
Growth Des. 2003, 3, 909–919. (b) Aakeroy, C. B.; Beatty, A. M.;
(10) Walsh, R. D. B.; Bradner, M. W.; Fleischman, S.; Morales, L. A.;
´
Moulton, B.; Rodrıguez-Hornedo, N.; Zaworotko, M. J. Chem.
Helfrich, B. A. Angew. Chem., Int. Ed. 2001, 40, 3240. (c)
Reddy, L. S.; Nangia, A.; Lynch, V. M. Cryst. Growth Des. 2004, 4,
Commun. 2003, 186.
€
89–94. (d) Aakeroy, C. B.; Desper, J.; Scott, B. M. T. Chem.
(11) (a) Almarsson, O.; Zaworotko, M. J. Chem. Commun. 2004, 1889–
1896. (b) McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.;
Cassidy, J.; Shet, M. S.; Mannion, R.; O'Donnel, E.; Park, A. Pharm.
Res. 2006, 23, 1888–1897. (c) Variankaval, N.; Wenslow, R.; Murry, J.;
Hartman, R.; Helmy, R.; Kwong, E.; Clas, S. D.; Dalton, C.; Santos, I.
Cryst. Growth Des. 2006, 6, 690–100.
Commun. 2006, 13, 1445. (e) Vishweshwar, P.; Nangia, A.; Lynch,
V. M. Cryst. Growth Des. 2003, 3, 783. (f) Videnova-Adrabinska, V.;
Etter, M. C. J. Chem. Crystallogr. 1995, 25, 823–829. (g) Leiserowitz,
L.; Nader, F. Acta Crystallogr., Sect. B: Struct. Sci. 1977, 33, 2719–
2733.
(36) (a) Bis, J. A.; Vishweshwar, P.; Weyna, D.; Zaworotko, M. J. Mol.
Pharmaceutics 2007, 4, 401–416. (b) Vishweshwar, P.; Nangia, A.;
Lynch, V. M. CrystEngComm 2003, 5, 164–168. (c) Papaefstathiou,
G. S.; MacGillivray, L. R. Org. Lett. 2001, 3, 3835–3838.
(37) (a) McMahon, J. A.; Bis, J. A.; Vishweshwar, P.; Shattock, T. R.;
McLaughlin, O. L.; Zaworotko, M. J. Z. Kristallogr. 2005, 220,
340–350. (b) Jagadeesh Babu, N.; Sreenivas Reddy, L.; Nangia, A.
Mol. Pharmaceutics 2007, 4, 417–434. (c) Leiserowitz, L.; Hagler,
A. T. Proc. R. Soc. London Series A 1983, 388, 133–175.
(12) Gillon, A. L.; Feeder, N.; Davey, R. J.; Storey, R. Cryst. Growth
Des. 2003, 3, 663–673.
(13) Desiraju, R. G. J. Chem. Soc., Chem. Commun. 1991, 426–428.
(14) (a) Stahl, H. P. In Towards Better Safety of Drugs and Pharmaceu-
tical Products; Braimar, D. D., Ed.; Biomedical Press: Elsevier North
Holland, 1980; pp 265-280. (b) Jeffrey, G. A. An Introduction to
Hydrogen Bonding; Oxford University Press: New York, 1997.
(15) Bettinetti, G.; Mura, P.; Sorrenti, M.; Faucci, M. T.; Negri, A.
J. Pharm. Sci. 1999, 88, 1133–1139.
(16) Stephenson, G. A.; Groleau, E. G.; Kleeman, R. L.; Xu, W.;
Rigsbee, D. R. J. Pharm. Sci. 1998, 87, 536–542.
(17) Khankari, R. K.; Law, D.; Grant, D. J. W. Int. J. Pharm. 1992, 82,
117–127.
(18) Chen, L. R.; Young, V. G., Jr.; Lechuga-Ballesteros, D.; Grant,
(38) (a) Shattock, T. R.; Arora, K. K.; Vishweshwar, P.; Zaworotko,
€
M. J. Cryst. Growth Des. 2008, 8, 4533–4545. (b) Aakeroy, C. B.;
Beatty, A. M.; Helfrich, B. A. J. Am. Chem. Soc. 2002, 124, 14425. (c)
Vishweshwar, P.; Nangia, A.; Lynch, V. M. J. Org. Chem. 2002, 67,
556–565.
(39) Kavuru, P.; Aborayes, D.; Arora, K. K.; Clarke, H. D.; Kennedy,
A.; Marshall, L.; Ong, T. T.; Pujari, T.; Wojtas, L.; Zaworotko,
M. J.; Perman, J. A.; Cryst. Growth Des. submitted for publication.
(40) Infantes, L.; Motherwell, S. CrystEngComm 2002, 4 (75), 454–461.
(41) Spek, A. L. PLATON, Molecular Geometry Program; University of
Utrecht: The Netherlands, May, 1997.
D. J. W. J. Pharm. Sci. 1999, 88, 1191–1200.
(19) (a) Apperly, D. C.; Basford, P. A.; Dallman, C. I.; Harris, R. K.;
Kinns, M.; Marshall, P. V.; Swanson, A. G. J. Pharm. Sci. 2005, 94,
516–523. (b) Zegarac, M.; Mestrovic, E.; Dumbovic, A.; Devcic, M.;
Tudja, P. WO 2007/080362 A1.